We are ready to support you.
[Webinar] Maintaining Momentum: Applying Recent Regulatory Guidance in the Midst of the Coronavirus
COVID-19
COVID-19
We applaud and support the efforts of teams developing treatments for COVID-19. As a proven leader in regulatory affairs, we understand the challenges that come with crucial studies. We stand ready to help those working for answers to navigate complex regulatory issues.
Future Proofing Inflammatory Bowel Disease Diagnosis & Clinical Trials
Slider

Service Solutions

Cato Research, Your Reliable Partner

Cato Research (CATO) is an international regulatory and clinical contract research organization (CRO) that has been delivering successful outcomes for its clients since 1988. Through highly qualified and experienced personnel located in offices across North America, Europe, Israel, and South Africa, supported by strategic alliances with selected regional CROs, CATO offers tried-and-trusted international coverage.

CATO has the advantage of integrated regulatory, clinical, and scientific expertise. Our highly talented and experienced international team offers services from preclinical through IND (or equivalent), clinical development, and marketing approval to Phase 4 postmarketing research. Our track record includes successes across many different health products, including drugs, biologics, vaccines, cell therapies (including stem cells), nutriceuticals, medical foods, devices, and diagnostics. In terms of diseases and indications, CATO has been involved in a wide variety of projects with a dominant focus in oncology, neurology/CNS, and rare and orphan drug indications. This experience includes leadership of, and involvement in some of the most challenging and innovative products.

Therapeutic Expertise

What our Sponsors say about us...

“…And a special thank you

"…And a special thank you to you and everyone at CATO.  You have been a very very valuable partner in this journey and we could not have gotten to where we are without you.  I deeply appreciate everything that you and your team at CATO have done for us and I look forward to continuing to have a strong relationship with CATO in the future as well.


Thank you again for all of your help.  We couldn't have done it without you!"

- Pharmaceutical Company Headquartered in Los Angeles, CA

Cato Research - International Contract Research Organization | Research Triangle Park, Durham, North Carolina
2017-11-21T21:12:43-05:00

- Pharmaceutical Company Headquartered in Los Angeles, CA

"…And a special thank you to you and everyone at CATO.  You have been a very very valuable partner in this journey and we could not have gotten to where we are without you.  I deeply appreciate everything that you and your team at CATO have done for us and I look forward to continuing to have a strong relationship with CATO in the future as well. Thank you again for all of your help.  We couldn't have done it without you!"

“…We have no reservations

"...We have no reservations recommending CATO to other companies requiring assistance with the monitoring of all phases of clinical trials..."

- Global Pharma Co.

Cato Research - International Contract Research Organization | Research Triangle Park, Durham, North Carolina
2017-11-22T15:48:10-05:00

- Global Pharma Co.

"...We have no reservations recommending CATO to other companies requiring assistance with the monitoring of all phases of clinical trials..."
0
0
Cato Research - International Contract Research Organization | Research Triangle Park, Durham, North Carolina

Upcoming Events

No event found!
Load More

Cato Research Blog

  • What’s New Health Canada?
    by Cato Research on May 7, 2020 at 9:44 pm

    By Alejandra Gomez Perez, M.Sc., Regulatory Affairs Associate   What’s New in: Therapeutic Products Directorate: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/what-new-drug-products-health-canada.html Biologics and Genetic Therapies Directorate: […]

  • New FDA Gudiances for April 2020 and Upcoming...
    by Cato Research on May 1, 2020 at 9:21 pm

    By Zachary Swan, PhD, RAC, Associate Director, Regulatory Affairs at CATO SMS    Special Interest Guidances/Information Date Posted Exemption and Exclusion from Certain Requirements of the Drug Supply Chain Security Act During the COVID-19 Public Health Emergency: Guidance for Industry – Final […]

Twitter @CatoResearch

LinkedIn Cato Research

Facebook @catoresearch

Searching for something else?